ADXS CC notes: All told, company spokespersons did a creditable job of assuaging investor concerns that ADXS-HPV might have caused the death of a patient with end-stage cervical cancer who was treated with ADXS-HPV 2.5 years prior to death.
Also working in ADXS’ favor is that the FDA has not placed a clinical hold on ADXS’s clinical trials of ADXS-HER2 and ADXS-PSA, which use essentially the same vector as ADXS-HPV.
My overall impression is that ADXS will come out of this incident ok, in due course.
Despite the above, the company’s long delay in disclosing this matter*, while the share price continued dropping, is reason enough for ADXS to remain in the penalty box for a while.
The stock is down 26% in AH trading, but it has recovered a little.
*The patient death that caused the clinical hold occurred in August.
News 
Market Data 
Discover 
